10-Q: Axsome Therapeutics Reports Q3 2024 Results: Revenue Growth Driven by Auvelity and Sunosi Sales

Axsome Therapeutics' Q3 2024 results show significant revenue growth driven by increased sales of Auvelity and Sunosi, alongside ongoing clinical development programs.

Summary

• Axsome Therapeutics reported a net loss of $64.6 million for the third quarter of 2024, compared to a net loss of $62.2 million for the same period in 2023.
• The company's total revenue for Q3 2024 was $104.8 million, a significant increase from $57.8 million in Q3 2023, primarily driven by product sales.
• Product sales, net, reached $103.7 million in Q3 2024, with Auvelity contributing $80.4 million and Sunosi contributing $23.4 million.
• License revenue was $0 for Q3 2024, compared to $65.7 million in Q3 2023, which was related to the Pharmanovia agreement.
• Royalty revenue from Sunosi sales by Pharmanovia was $1.0 million in Q3 2024, compared to $0.7 million in Q3 2023.
• Research and development expenses increased to $45.4 million in Q3 2024 from $28.8 million in Q3 2023, due to ongoing clinical trials.
• Selling, general, and administrative expenses also increased to $95.6 million in Q3 2024 from $83.2 million in Q3 2023, due to commercial activities.
• The company's cash and cash equivalents were $327.3 million as of September 30, 2024, down from $386.2 million at the end of 2023.
• The company believes its existing cash will be sufficient to fund its anticipated operating cash requirements for at least twelve months following the date of this filing.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there is strong revenue growth and ongoing clinical development, the increasing net loss and reliance on future capital raises temper the overall outlook. The company is making progress but faces financial challenges.

Positives

• Significant revenue growth driven by increased sales of Auvelity and Sunosi.
• The company believes its existing cash will be sufficient to fund its anticipated operating cash requirements for at least twelve months following the date of this filing.
• The Fifth Amendment to the Loan Agreement provides additional financial flexibility.
• The company is actively advancing its clinical development programs.

Negatives

• The company reported a net loss of $64.6 million for Q3 2024.
• Operating expenses, including research and development and selling, general, and administrative costs, have increased.
• Cash and cash equivalents decreased from $386.2 million at the end of 2023 to $327.3 million as of September 30, 2024.

Risks

• The company has incurred operating losses since its inception and expects to continue to incur operating losses and may never become profitable.
• The company's ability to achieve profitability depends on a number of factors, including its ability to obtain regulatory approval for its product candidates, successfully complete any post-approval regulatory obligations and successfully commercialize its product candidates alone or in partnership with third parties.
• The company may need to raise additional capital to fund its operations.
• The company is subject to a number of factors that can affect its operating results and financial condition, including the results of clinical testing and trial activities of the Companys product candidates; the Companys ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Companys products; the Companys ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Companys ability to raise additional capital.
• The company has a limited number of contract manufacturers for its products and may have only one manufacturer or supplier for its products at times.

Future Outlook

The company believes its existing cash will be sufficient to fund its anticipated operating cash requirements for at least twelve months following the date of this filing. The company expects that its expenses will increase primarily due to the commercialization of Auvelity and Sunosi while continuing to further develop the company's pipeline assets.

Industry Context

The announcement reflects the ongoing challenges and opportunities in the biopharmaceutical industry, where companies are focused on developing and commercializing innovative therapies for central nervous system disorders. The increase in revenue from Auvelity and Sunosi indicates a growing market acceptance of these products, while the rise in R&D expenses highlights the continued investment in future growth.

Comparison to Industry Standards

• Axsome's revenue growth in Q3 2024 is notable compared to many other commercial-stage biopharmaceutical companies, particularly those focused on CNS disorders.
• The increase in R&D spending is consistent with industry trends, where companies are investing heavily in clinical trials to expand their product pipelines.
• The company's cash position is relatively strong, providing a buffer for ongoing operations and future development activities.
• However, the net loss reported by Axsome is not uncommon for companies in this stage of development, as they often prioritize growth and clinical development over immediate profitability.
• Compared to companies like Jazz Pharmaceuticals, which previously held the rights to Sunosi, Axsome is demonstrating a strong ability to commercialize and grow sales of the product.
• The company's focus on novel mechanisms of action and differentiated products aligns with the industry's push for innovative therapies.

Legal Proceedings

• The company is involved in ongoing securities class action and shareholder derivative litigation.
• The company has commenced patent infringement actions against Teva Pharmaceuticals, Inc. relating to Teva's Abbreviated New Drug Application for Auvelity.
• The company has commenced patent infringement actions against Hikma and other drug companies relating to each defendant's ANDA for Sunosi.
• The company entered into a settlement agreement with Unichem resolving patent litigation related to Sunosi.
• The company reached an agreement with Sandoz Inc. to dismiss the patent litigation related to Sunosi.

Related Party Transactions

• The company recorded royalty expense of $6.0 million for the nine months ended September 30, 2024, for royalty due to Antecip, an entity owned by Axsomes Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., equal to 3.0 % of Auvelity net sales.

Stakeholder Impact

• Shareholders may be concerned about the increasing net loss and the need for potential future capital raises.
• Employees may be affected by the company's financial performance and any potential restructuring or cost-cutting measures.
• Customers (patients and healthcare providers) may benefit from the availability of new therapies, but may also be affected by pricing and reimbursement decisions.
• Suppliers and creditors may be impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• Continue commercialization efforts for Auvelity and Sunosi.
• Advance ongoing Phase 3 clinical trials for solriamfetol, AXS-05, and AXS-12.
• Resubmit the NDA for AXS-07 for the acute treatment of migraine.
• Evaluate other product candidates for CNS disorders.

Key Dates

Keywords

Axsome Therapeutics, Auvelity, Sunosi, CNS disorders, clinical trials, revenue growth, pharmaceutical, biopharmaceutical, regulatory approval, product sales